{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:42:38Z","timestamp":1767706958597},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T00:00:00Z","timestamp":1304553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00345-011-0681-4","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T09:09:59Z","timestamp":1304500199000},"page":"415-422","source":"Crossref","is-referenced-by-count":19,"title":["Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy"],"prefix":"10.1007","volume":"29","author":[{"given":"D. R.","family":"Yates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,5]]},"reference":[{"key":"681_CR1","doi-asserted-by":"crossref","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. doi: 10.1016\/j.eururo.2011.03.017","DOI":"10.1016\/j.eururo.2011.03.017"},{"key":"681_CR2","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"681_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247","journal-title":"Eur Urol"},{"key":"681_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","volume":"172","author":"GN Thalmann","year":"2004","unstructured":"Thalmann GN, Markwalder R, Shahin O et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70","journal-title":"J Urol"},{"key":"681_CR5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666","journal-title":"J Clin Oncol"},{"key":"681_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","volume":"151","author":"CL Amling","year":"1994","unstructured":"Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31","journal-title":"J Urol"},{"key":"681_CR7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283","journal-title":"J Urol"},{"key":"681_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","volume":"22","author":"FJ Bianco Jr","year":"2004","unstructured":"Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA et al (2004) Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22:290","journal-title":"Urol Oncol"},{"key":"681_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","volume":"27","author":"RE Hautmann","year":"2009","unstructured":"Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 27:347","journal-title":"World J Urol"},{"key":"681_CR10","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","volume":"4","author":"GS Kulkarni","year":"2007","unstructured":"Kulkarni GS, Finelli A, Fleshner NE et al (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4:e284","journal-title":"PLoS Med"},{"key":"681_CR11","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","volume":"115","author":"GS Kulkarni","year":"2009","unstructured":"Kulkarni GS, Alibhai SM, Finelli A et al (2009) Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115:5450","journal-title":"Cancer"},{"key":"681_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner SP, Tangen CM, Sucharew H et al (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27:155","journal-title":"Urol Oncol"},{"key":"681_CR13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169:1706","journal-title":"J Urol"},{"key":"681_CR14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/era.09.35","volume":"9","author":"FM Martin","year":"2009","unstructured":"Martin FM, Kamat AM (2009) Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9:815","journal-title":"Expert Rev Anticancer Ther"},{"key":"681_CR15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","volume":"164","author":"E Solsona","year":"2000","unstructured":"Solsona E, Iborra I, Dumont R et al (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685","journal-title":"J Urol"},{"key":"681_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00345-009-0429-6","volume":"27","author":"KG Nepple","year":"2009","unstructured":"Nepple KG, Aubert HA, Braasch MR (2009) Combination of BCG and interferon intravesical immunotherapy: an update. World J Urol 27:343","journal-title":"World J Urol"},{"key":"681_CR17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi FN, Smith BJ, O\u2019Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344","journal-title":"Urol Oncol"},{"key":"681_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher BL, Joudi FN, Maymi JL (2008) Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology 71:297","journal-title":"Urology"},{"key":"681_CR19","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple KG, Lightfoot AJ, Rosevear HM et al (2010) Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 184:1915","journal-title":"J Urol"},{"key":"681_CR20","first-page":"313","volume":"4","author":"M Kowalski","year":"2010","unstructured":"Kowalski M, Entwistle J, Cizeau J et al (2010) A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Devel Ther 4:313","journal-title":"Drug Des Devel Ther"},{"key":"681_CR21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstrom","year":"1999","unstructured":"Malmstrom PU, Wijkstrom H, Lundholm C (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124","journal-title":"J Urol"},{"key":"681_CR22","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729","journal-title":"J Clin Oncol"},{"key":"681_CR23","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","volume":"20","author":"G Dalbagni","year":"2002","unstructured":"Dalbagni G, Russo P, Sheinfeld J et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193","journal-title":"J Clin Oncol"},{"key":"681_CR24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Gacci M et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66:726","journal-title":"Urology"},{"key":"681_CR25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Perdona S, Damiano R et al (2010) Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116:1893","journal-title":"Cancer"},{"key":"681_CR26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543","journal-title":"J Clin Oncol"},{"key":"681_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","volume":"84","author":"M Porena","year":"2010","unstructured":"Porena M, Del Zingaro M, Lazzeri M et al (2010) Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 84:23","journal-title":"Urol Int"},{"key":"681_CR28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","volume":"56","author":"A Bohle","year":"2009","unstructured":"Bohle A, Leyh H, Frei C et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56:495","journal-title":"Eur Urol"},{"key":"681_CR29","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1464-410X.2010.09496.x","volume":"106","author":"P Gontero","year":"2010","unstructured":"Gontero P, Cattel L, Paone TC et al (2010) Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int 106:1652","journal-title":"BJU Int"},{"key":"681_CR30","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"JM McKiernan","year":"2006","unstructured":"McKiernan JM, Masson P, Murphy AM et al (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075","journal-title":"J Clin Oncol"},{"key":"681_CR31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"MA Laudano","year":"2010","unstructured":"Laudano MA, Barlow LJ, Murphy AM et al (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134","journal-title":"Urology"},{"key":"681_CR32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","volume":"27","author":"LJ Barlow","year":"2009","unstructured":"Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331","journal-title":"World J Urol"},{"key":"681_CR33","doi-asserted-by":"crossref","unstructured":"Chen CH, Yang HJ, Shun CT et al. (2010) A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol Oncol. doi: 10.1016\/j.urolonc.2010.06.012","DOI":"10.1016\/j.urolonc.2010.06.012"},{"key":"681_CR34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","volume":"27","author":"J Alfred Witjes","year":"2009","unstructured":"Alfred Witjes J, Hendricksen K, Gofrit O et al (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 27:319","journal-title":"World J Urol"},{"key":"681_CR35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Hendricksen K et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182:1313","journal-title":"J Urol"},{"key":"681_CR36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2010","unstructured":"Colombo R, Salonia A, Leib Z et al (2010) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107:912","journal-title":"BJU Int"},{"key":"681_CR37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","volume":"51","author":"M Brausi","year":"1998","unstructured":"Brausi M, Campo B, Pizzocaro G et al (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51:506","journal-title":"Urology"},{"key":"681_CR38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","volume":"27","author":"SM Di Stasi","year":"2009","unstructured":"Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27:325","journal-title":"World J Urol"},{"key":"681_CR39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777","journal-title":"J Urol"},{"key":"681_CR40","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","volume":"165","author":"R Waidelich","year":"2001","unstructured":"Waidelich R, Stepp H, Baumgartner R et al (2001) Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904","journal-title":"J Urol"},{"key":"681_CR41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","volume":"61","author":"AP Berger","year":"2003","unstructured":"Berger AP, Steiner H, Stenzl A et al (2003) Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61:338","journal-title":"Urology"},{"key":"681_CR42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pdpdt.2010.08.005","volume":"7","author":"LS Lee","year":"2010","unstructured":"Lee LS, Thong PS, Olivo M et al (2010) Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy\u2013A potential bladder sparing option for high risk non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 7:213","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"681_CR43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000473832","volume":"29","author":"AP Meijden Van der","year":"1996","unstructured":"Van der Meijden AP, Hall RR, Macaluso MP (1996) Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29:19","journal-title":"Eur Urol"},{"key":"681_CR44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"W Oosterlinck","year":"2011","unstructured":"Oosterlinck W, Kirkali Z, Sylvester R et al (2011) Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus calmette-guerin and with bacillus calmette-guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 59:438","journal-title":"Eur Urol"},{"key":"681_CR45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43","journal-title":"Lancet Oncol"},{"key":"681_CR46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","volume":"28","author":"BN Breyer","year":"2010","unstructured":"Breyer BN, Whitson JM, Carroll PR et al (2010) Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 28:510","journal-title":"Urol Oncol"},{"key":"681_CR47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00345-009-0474-1","volume":"28","author":"E Chiong","year":"2010","unstructured":"Chiong E, Esuvaranathan K (2010) New therapies for non-muscle-invasive bladder cancer. World J Urol 28:71","journal-title":"World J Urol"},{"key":"681_CR48","doi-asserted-by":"crossref","unstructured":"Horinaga M, Fukuyama R, Iida M et al. (2010) Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 76:1267 e1261","DOI":"10.1016\/j.urology.2010.03.028"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-011-0681-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-011-0681-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T09:57:44Z","timestamp":1560160664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-011-0681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,5]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1007\/s00345-011-0681-4","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,5]]}}}